The Impairment of Social and Environmental Relationships in Patients With Heart Failure Correlated With Therapeutic Class.

Background and objectives Heart failure (HF) significantly influences the quality of life, both physically and emotionally, as well as social and environmental relationships. One major objective of HF treatment is to maintain or improve the quality of life. The aims of the study were to assess the impact of HF on social relationships and the relationship with the environment, according to therapeutic class and the presence of comorbidities, and to identify predictive factors for the impairment of these dimensions of the quality of life.

The Rare Condition of Left Ventricular Non-Compaction and Reverse Remodeling.

Left ventricular non-compaction (LVNC) is a rare disease defined by morphological criteria, consisting of a two-layered ventricular wall, a thin compacted epicardial layer, and a thick hyper-trabeculated myocardium layer with deep recesses. Controversies still exist regarding whether it is a distinct cardiomyopathy (CM) or a morphological trait of different conditions. This review analyzes data from the literature regarding diagnosis, treatment, and prognosis in LVNC and the current knowledge regarding reverse remodeling in this form of CM.

Usefulness of the Edmonton Frail Scale in Assessing the Impact of Heart Failure on Frailty.

Background/aim: The association of frailty with heart failure (HF) is common in the elderly, and its presence is a poor prognostic factor; it increases the risk of falls, disability, hospitalization, and mortality. The aim of this prospective study was to assess the incidence of physical frailty in patients with HF and the role of physical exercise in improving physical performance.

Patients And Methods: A total of 141 patients with musculoskeletal pathology, aged over 65 years, who followed a specific physical training program were included.

Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure.

Sacubitril/valsartan (S/V) is a pharmaceutical strategy that increases natriuretic peptide levels by inhibiting neprilysin and regulating the renin-angiotensin-aldosterone pathway, blocking AT1 receptors. The data for this innovative medication are mainly based on the PARADIGM-HF study, which included heart failure with reduced ejection fraction (HFrEF)-diagnosed patients and indicated a major improvement in morbidity and mortality when S/V is administrated compared to enalapril. A large part of the observed favorable results is related to significant reverse cardiac remodeling confirmed in two prospective trials, PROVE-HF and EVALUATE-HF.

A Narrative Review of the Classical and Modern Diagnostic Methods of the No-Reflow Phenomenon.

The incidence of the no-reflow (NR) phenomenon varies depending on the diagnostic criteria used. If just the angiographic criteria are considered (i.e.

Acute coronary syndromes in diabetic patients, outcome, revascularization, and antithrombotic therapy.

Diabetes exacerbates the progression of atherosclerosis and is associated with increased risk of developing acute coronary syndrome (ACS). Approximatively 25-30% of patients admitted for ACS have diabetes. ACS occurs earlier in diabetics and is associated with increased mortality and a higher risk of recurrent ischemic events.

Chronological Age in Different Bone Development Stages: A Retrospective Comparative Study.

The assessment of an individual's development by investigating the skeletal maturity is of much use in various medical fields. Skeletal maturity can be estimated by evaluating the morphology of the cervical vertebrae. The aim of this study was to conduct comparisons of the chronological age in different bone development stages.